CRISPR Therapeutics is trading at 29.63 as of the 2nd of January 2025, a 6.2 percent decrease since the beginning of the trading day. The stock's open price was 31.59. CRISPR Therapeutics has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of December 2024 and ending today, the 2nd of January 2025. Click here to learn more.
Although CRISPR Therapeutics' alpha and beta are two of the key measurements used to evaluate CRISPR Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CRISPR Therapeutics stock to make a market-neutral strategy. Peer analysis of CRISPR Therapeutics could also be used in its relative valuation, which is a method of valuing CRISPR Therapeutics by comparing valuation metrics with similar companies.